http://orcid.org/0000-0002-2661-6183
References
- Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ng KP, Colombo A, et al. Geographic and temporal trends in isolation and antifungal susceptibility of candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol. 2008;46(3):842–849.10.1128/JCM.02122-07
- Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6(9):e24198.10.1371/journal.pone.0024198
- Tortorano AM, Prigitano A, Dho G, Grancini A, Passera M, Group E-FS. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61(3):389–393.10.1099/jmm.0.037895-0
- Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–2029.10.1056/NEJMoa021585
- Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006;42(2):244–251.10.1086/499057
- Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47(10):3149–3154.10.1128/AAC.47.10.3149-3154.2003
- Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother. 2007;59(4):767–771.10.1093/jac/dkl555
- Fernandez-Ruiz M, Aguado JM, Almirante B, Lora-Pablos D, Padilla B, Puig-Asensio M, et al. Initial use of echinocandins does not negatively influence outcome in candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014;58(10):1413–1421.10.1093/cid/ciu158
- Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection. 2006;34(6):345–348.10.1007/s15010-006-5613-7
- Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47(4):1187–1192.10.1128/AAC.47.4.1187-1192.2003
- CLSI. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved Standard-Third Edition. CLSI document M27-A3. Wayne (PA): Clinical and Laboratory Standard Institute; 2008.
- Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011;14(3):164–176.10.1016/j.drup.2011.01.004
- Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161–189.10.1086/cid.2004.38.issue-2
- Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration‐dependent activity. J Infect Dis. 2004;190(8):1464–1471.10.1086/jid.2004.190.issue-8
- Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005;49(12):5058–5068.10.1128/AAC.49.12.5058-5068.2005
- Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother. 2012;56(11):5875–5882.10.1128/AAC.01102-12
- Mazzei T, Novelli A. Pharmacological properties of antifungal drugs with a focus on anidulafungin. Drugs. 2009;69:79–90.10.2165/11315550-000000000-00000